The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients A Multicenter Real-Life Study

Basit Öğe Kaydı
dc.authoridBeşiroğlu, Mehmet/0000-0002-1171-8320
dc.authoridErgun, Yakup/0000-0003-4784-6743;
dc.authorwosidBeşiroğlu, Mehmet/AEQ-3080-2022
dc.authorwosidDemirci, Ayşe/GWZ-5265-2022
dc.authorwosidErgun, Yakup/N-3273-2018
dc.authorwosidSendur, Mehmet Ali Nahit/H-7555-2014
dc.contributor.authorAkdeniz, Nadiye
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorInanc, Mevlude
dc.contributor.authorUncu, Dogan
dc.contributor.authorErgun, Yakup
dc.contributor.authorKucukoner, Mehmet
dc.contributor.authorDemirci, Ayse
dc.date.accessioned2024-05-19T14:41:07Z
dc.date.available2024-05-19T14:41:07Z
dc.date.issued2022
dc.departmentİstinye Üniversitesien_US
dc.description.abstractObjectiveThe aim of the study is to compare the efficacy and safety of 3 chemotherapy regimens used as first-line treatments in the real-life management of metastatic pancreatic cancer.MethodsA total of 218 patients were included in this multicenter study. Gemcitabine (Gem, n = 71), gemcitabine-cisplatin (Gem-Cis, n = 91), and FOLFIRINOX (a combination of leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin [FFX], n = 56) treatments were compared.ResultsOverall response rate was significantly higher in the FFX group (50.0%) than in the Gem (28.2%) and Gem-Cis (27.5%) groups (P = 0.010). Median progression-free survival (8.4 vs 4.6 and 5.5 months, respectively, P < 0.001) and overall survival (16.4 vs 8.1 and 8.7 months, respectively, P = 0.002) were significantly longer in the FFX group than in the Gem and Gem-Cis groups. Toxicity of any grade was noted in 46 (64.8%), 56 (61.5%), and 49 (87.5%) patients in the Gem, Gem-Cis, and FFX groups, respectively (P = 0.003).ConclusionsIn our study, FFX regimen provides a significant advantage over the other treatment regimens in terms of response rates and survival. Treatment toxicity was more frequent but manageable with the FFX regimen.en_US
dc.identifier.doi10.1097/MPA.0000000000002167
dc.identifier.endpage1159en_US
dc.identifier.issn0885-3177
dc.identifier.issn1536-4828
dc.identifier.issue9en_US
dc.identifier.pmid37078939en_US
dc.identifier.scopus2-s2.0-85153411794en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1153en_US
dc.identifier.urihttps://doi.org10.1097/MPA.0000000000002167
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5065
dc.identifier.volume51en_US
dc.identifier.wosWOS:000989541800018en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofPancreasen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectEfficacyen_US
dc.subjectFirst-Line Chemotherapyen_US
dc.subjectFolfirinoxen_US
dc.subjectGemcitabineen_US
dc.subjectGemcitabine-Cisplatinen_US
dc.subjectMetastatic Pancreatic Canceren_US
dc.titleThe Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients A Multicenter Real-Life Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu